Efficacy of Timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC)
نویسندگان
چکیده
Methods Subjects 5 years and older with ARC with/without asthma received once-daily 2800 BAU sublingual grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, ~15μg Phl p5) or placebo starting approximately 16 weeks before and continuing throughout the 2009 grass pollen season (GPS). Subjects used daily e-diaries to record ARC symptoms and use of symptomatic medications from randomization through study end (approximately 24 weeks). The primary efficacy endpoint comprised the average total combined daily symptom and medication score (TCS) during the entire GPS. Secondary endpoints included average daily symptom score (DSS) and average daily medication score (DMS). Safety was assessed by monitoring adverse events (AEs).
منابع مشابه
Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials
Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials Background: Specific immunotherapy is the only treatment of IgE-mediated allergic diseases with the potential to modify the underlying cause of disease and prevent disease progression or even cure ...
متن کاملBudget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis
BACKGROUND Grass pollen-induced allergic rhinoconjunctivitis constitutes a large burden for society. Up to 20% of European and United States (US) populations suffer from respiratory allergies, including grass pollen-induced allergic rhinoconjunctivitis. The majority of patients are treated with symptomatic medications; however, a large proportion remains uncontrolled despite use of such treatme...
متن کاملEfficacy and Safety of 5–Grass-Pollen Sublingual Immunotherapy Tablets in Pediatric Allergic Rhinoconjunctivitis
STUDY POPULATION. Subjects were 278 children (age: 5–14 years) with seasonal grass pollen-induced allergic rhinoconjunctivitis for 2 years. Allergy was confirmed by a timothy grass-specific immunoglobulin E (IgE) level of at least class 2 and a wheal diameter of 3 mm in a skin-prick test containing 5 grass pollens included in the SLIT tablet (orchard, meadow, perennial rye, sweet vernal, and ti...
متن کاملEconomic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
BACKGROUND Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The o...
متن کاملPD14 - Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen
Background The aim of this non-interventional study was to document the impact of a sublingual allergen immunotherapy (AIT) with Oralair 5-grass pollen tablets (Stallergenes, France) on symptom severity, use of symptomatic medication and tolerability in patients with grass pollen-induced allergic rhinoconjunctivitis (RC) over 2 years of routine medical practice treatment. This poster focuses on...
متن کامل